BioNxt is thrilled to announce that it has acquired cutting-edge coating and cutting equipment to expand its commercial manufacturing capabilities at its Vektor Pharma TF GmbH facility in Baden-Württemberg, Germany.
This CE certified equipment will allow the Company to produce its oral dissolvable (“ODF”) and transdermal (“TDS”) drug formulation products, as well as ODF biosensor products for the further development and commercialization of key products in BioNxt’s pipeline. This new equipment also opens up the potential for strategic contract research and development opportunities.
State-of-the-art coating and cutting technology has arrived from Germany! Our fully automated coating machine is equipped with a sensor-controlled coating thickness measurement system for precision results. Meanwhile, our cutting machine features a camera-controlled laser cutting system and a pick and place robot automation.
The best part? Both machines are certified by the European Union for health, safety, and environmental protection. Get ready to experience the future of manufacturing with these cutting-edge German machines!
BioNxt is gearing up for a big year in 2023, with a focus on building out its commercial manufacturing capabilities. With products quickly advancing towards commercialization and potential contract development and manufacturing opportunities available, the company is firmly committed to achieving in-house commercial capability in record time.
To ensure success, BioNxt is planning a flexible production line for pivotal trial materials and transdermal and oral dissolvable final commercial products. CEO & Director Hugh Rogers is confident that the company will be able to meet this goal.
BioNxt’s subsidiary, Vektor, is a German narcotics manufacturer and developer based in Biberach, Baden-Württemberg. For over 10 years, the company and its team have been at the forefront of designing, testing, and producing innovative drug delivery systems, such as transdermal patches and sub-lingual strips, for the delivery of active pharmaceutical ingredients for treating pain and neurological conditions.
The global pharmaceutical drug delivery market is projected to reach a whopping USD 2,047 billion by 2030, according to Precedence Research, with the market size valued at USD 1,525 billion in 2022.
About BioNxt Solutions Inc.
BioNxt Solutions Inc. is a forward-thinking bioscience accelerator that is revolutionizing the way we view drug formulations and delivery systems, diagnostic screening tests and active pharmaceutical production.
By utilizing precision transdermal and oral dissolvable drug formulations, rapid and low-cost infectious disease and oral health screening tests and standardizing and clinically evaluating emerging active pharmaceutical ingredients for neurological applications, BioNxt Solutions Inc. is paving the way for medical advancement in Europe.
With research and development operations based in North America and Europe, particularly in Germany, BioNxt Solutions Inc. is currently focused on obtaining regulatory approval and commercializing medical products for European markets.